Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
4.51 HKD | 0.00% | +9.73% | -36.03% |
Mar. 07 | OrbusNeich Medical Group’s Profit Up 144% in 2023 | MT |
Mar. 07 | OrbusNeich Medical Group Holdings Limited Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- With a P/E ratio at 11.47 for the current year and 9.6 for next year, earnings multiples are highly attractive compared with competitors.
- The company has a low valuation given the cash flows generated by its activity.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- The opinion of analysts covering the stock has improved over the past four months.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
Ratings chart - Surperformance
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-36.03% | 478M | - | ||
+8.29% | 124B | A- | ||
-5.61% | 11.17B | A- | ||
+4.83% | 9.17B | C | ||
+39.60% | 5.59B | B+ | ||
-22.04% | 4.71B | C | ||
+8.39% | 3.44B | C- | ||
-6.28% | 2.88B | B- | ||
-10.23% | 2.11B | - | - | |
-5.99% | 2.09B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 6929 Stock
- Ratings OrbusNeich Medical Group Holdings Limited